News | September 17, 2024
Wacker collaborates with MinervaX for prophylactic vaccine targeting Group B streptococcus
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
ALS patients experience neuroinflammation and rapid neurodegeneration
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
The BPaLM regimen, which consists four-drug combination – Bedaquiline, Pretomanid, Linezolid and Moxifloxacin, has been proven to be safe, more effective and a quicker treatment option than the previous MDR-TB treatment procedure
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
Subscribe To Our Newsletter & Stay Updated
